Wockhardt says Himachal Pradesh drug regulator suspends product
MUMBAI (Reuters) - Indian drugmaker Wockhardt Ltd, which has been hit by a slew of overseas regulatory rebukes due to poor production quality, said the regulator in Himachal Pradesh has suspended the manufacture and sale of a product.
The state's drug controller suspended the manufacture, sale or distribution of fixed dose combination of Dicyclomine Hydrochloride IP 10mg, Tramadol Hydrochloride IP 50mg and Acetamenophen IP 325mg, the company said in a statement on Wednesday.
Wockhardt did not give the reason for the suspension.
But Navneet Marwah, Himachal Pradesh's drug regulator, told Reuters that some of the chemicals which the company used in making a painkiller sold under the brandname of Spasmo Proxyvon Plus have been banned by the Indian government.
"We got some complaints from the consumers and acted on that," Marwah said. He said the state regulator has sent a report to the federal drug regulator and the suspension will remain in force until a decision by the federal agency.
Wockhardt said the product contributed less than 3 percent of the consolidated sales of the company in the financial year that ended on March 31. The company will appeal to the state government to revoke the suspension, it said.
Wockhardt has been barred from exporting drugs from some of its plants in India to the United States, its largest market, and Britain, in the last one year due to poor manufacturing quality.
(Reporting by Sumeet Chatterjee; Editing by Anupama Dwivedi)
- Tweet this
- Share this
- Digg this
- U.S. strikes have slowed Iraq militants but not weakened them - Pentagon
- Comedian Joan Rivers remains in serious condition at N.Y. hospital
- Exclusive: Reliance plans $13 billion projects including new refinery
- Ukraine seeks to join NATO; defiant Putin compares Kiev to Nazis
- Swedish carrier backs out as first Bombardier CSeries operator
India's economy grew by a faster-than-expected 5.7 percent in the three months through June, its fastest pace in two-and-a- half years, helped by a rebound in manufacturing and mining sectors, government data showed on Friday. Full Article
Exclusive: Reliance plans $13 billion projects including new refinery. Full Article
In race for bigger margins, drug makers willing to lose the India "advantage". Full Article